肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 ESMO临床实践指南：免疫治疗在早期和晚期肾细胞癌中的应用（更新版）

2021-09-23 欧洲肿瘤内科学会 Annals of Oncology

肾细胞癌

2021年9月，欧洲肿瘤内科学会(ESMO)发布了免疫治疗在早期和晚期肾细胞癌中的应用指南。指南主要聚焦近期关于肾细胞癌免疫治疗的相关内容。

中文标题：

2021 ESMO临床实践指南：免疫治疗在早期和晚期肾细胞癌中的应用（更新版）

英文标题：

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

发布机构：

欧洲肿瘤内科学会

发布日期：

2021-09-23

简要介绍：

2021年9月，欧洲肿瘤内科学会(ESMO)发布了免疫治疗在早期和晚期肾细胞癌中的应用指南。指南主要聚焦近期关于肾细胞癌免疫治疗的相关内容。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ESMO临床实践指南：免疫治疗在早期和晚期肾细胞癌中的应用（更新版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ca8141c0022025df, title=2021 ESMO临床实践指南：免疫治疗在早期和晚期肾细胞癌中的应用（更新版） , enTitle=ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma, guiderFrom=Annals of Oncology, authorId=0, author=, summary=2021年9月，欧洲肿瘤内科学会(ESMO)发布了免疫治疗在早期和晚期肾细胞癌中的应用指南。指南主要聚焦近期关于肾细胞癌免疫治疗的相关内容。, cover=https://img.medsci.cn/20211011/1633965027924_5579292.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Thu Sep 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年9月，欧洲肿瘤内科学会(ESMO)发布了免疫治疗在早期和晚期肾细胞癌中的应用指南。指南主要聚焦近期关于肾细胞癌免疫治疗的相关内容。</span></p>, tagList=[TagDto(tagId=897, tagName=肾细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=897, guiderKeyword=肾细胞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3428, appHits=74, showAppHits=0, pcHits=1883, showPcHits=3354, likes=0, shares=8, comments=9, approvalStatus=1, publishedTime=Mon Oct 11 23:16:37 CST 2021, publishedTimeString=2021-09-23, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Oct 11 23:12:48 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 15:06:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ESMO临床实践指南：免疫治疗在早期和晚期肾细胞癌中的应用（更新版）.pdf)])
2021 ESMO临床实践指南：免疫治疗在早期和晚期肾细胞癌中的应用（更新版）.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1059978, encodeId=14b810599e8f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211006/85a8506959574e35b49a036fbc534351/76d93dcc85024df68e08916ad97057f4.jpg, createdBy=440b5626313, createdName=priuce0, createdTime=Wed Oct 13 00:22:05 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059833, encodeId=d40010598339e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c355400091, createdName=ms8000001445155228, createdTime=Tue Oct 12 15:47:22 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059664, encodeId=b20f1059664eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eee3077953, createdName=947107826, createdTime=Tue Oct 12 09:03:29 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059656, encodeId=cdf510596566b, content=啵啵啵啵, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:40:14 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059653, encodeId=a5731059653b8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:39:01 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-13 priuce0

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1059978, encodeId=14b810599e8f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211006/85a8506959574e35b49a036fbc534351/76d93dcc85024df68e08916ad97057f4.jpg, createdBy=440b5626313, createdName=priuce0, createdTime=Wed Oct 13 00:22:05 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059833, encodeId=d40010598339e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c355400091, createdName=ms8000001445155228, createdTime=Tue Oct 12 15:47:22 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059664, encodeId=b20f1059664eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eee3077953, createdName=947107826, createdTime=Tue Oct 12 09:03:29 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059656, encodeId=cdf510596566b, content=啵啵啵啵, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:40:14 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059653, encodeId=a5731059653b8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:39:01 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 ms8000001445155228

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1059978, encodeId=14b810599e8f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211006/85a8506959574e35b49a036fbc534351/76d93dcc85024df68e08916ad97057f4.jpg, createdBy=440b5626313, createdName=priuce0, createdTime=Wed Oct 13 00:22:05 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059833, encodeId=d40010598339e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c355400091, createdName=ms8000001445155228, createdTime=Tue Oct 12 15:47:22 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059664, encodeId=b20f1059664eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eee3077953, createdName=947107826, createdTime=Tue Oct 12 09:03:29 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059656, encodeId=cdf510596566b, content=啵啵啵啵, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:40:14 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059653, encodeId=a5731059653b8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:39:01 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 947107826

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1059978, encodeId=14b810599e8f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211006/85a8506959574e35b49a036fbc534351/76d93dcc85024df68e08916ad97057f4.jpg, createdBy=440b5626313, createdName=priuce0, createdTime=Wed Oct 13 00:22:05 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059833, encodeId=d40010598339e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c355400091, createdName=ms8000001445155228, createdTime=Tue Oct 12 15:47:22 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059664, encodeId=b20f1059664eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eee3077953, createdName=947107826, createdTime=Tue Oct 12 09:03:29 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059656, encodeId=cdf510596566b, content=啵啵啵啵, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:40:14 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059653, encodeId=a5731059653b8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:39:01 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 微探

    啵啵啵啵

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1059978, encodeId=14b810599e8f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211006/85a8506959574e35b49a036fbc534351/76d93dcc85024df68e08916ad97057f4.jpg, createdBy=440b5626313, createdName=priuce0, createdTime=Wed Oct 13 00:22:05 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059833, encodeId=d40010598339e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c355400091, createdName=ms8000001445155228, createdTime=Tue Oct 12 15:47:22 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059664, encodeId=b20f1059664eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eee3077953, createdName=947107826, createdTime=Tue Oct 12 09:03:29 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059656, encodeId=cdf510596566b, content=啵啵啵啵, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:40:14 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059653, encodeId=a5731059653b8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 12 07:39:01 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 微探

    学习学习

    0

相关指南

2021临床共识声明：遗传性肾细胞癌的遗传风险评估

国外肿瘤科相关专家小组（统称） · 2021-08-03

2019 HKUA_HKSUO共识声明：转移性肾细胞癌的管理

香港泌尿外科协会(HKUA,Hong Kong Urological Association) · 2021-04-17

肾细胞癌分子病理研究进展及检测专家共识（2020版）

中华医学会病理学分会 · 2020-12-10

2020 EAU指南：肾细胞癌（更新版）

暂未更新 · 2020-03-26

2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗

肿瘤免疫治疗学会(SITC,Society for Immunotherapy of Cancer) · 2019-12-20

2019 EAU指南：肾细胞癌（更新版）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2019-02-22

拓展阅读

2014 ESMO临床实践指南：肾细胞癌的诊治及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2014-09-16

2014 EAU指南：肾细胞癌（更新版）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2015-01-20

2016 ESMO临床实践指南：肾细胞癌的诊断，治疗及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

2019 ESMO临床实践指南：肾细胞癌的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2019-02-21

2019 EAU指南：肾细胞癌（更新版）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2019-02-22

2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗

肿瘤免疫治疗学会(SITC,Society for Immunotherapy of Cancer) · 2019-12-20